絞り込み

16644

広告

An overview of health issues and development in a large clinical cohort of children with Angelman syndrome.

著者 Bindels-de Heus KGCB , Mous SE , Ten Hooven-Radstaake M , van Iperen-Kolk BM , Navis C , Rietman AB , Ten Hoopen LW , Brooks AS , , Elgersma Y , Moll HA , de Wit MY
Am J Med Genet A.2019 Nov 15 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

This study presents a broad overview of health issues and psychomotor development of 100 children with Angelman syndrome (AS), seen at the ENCORE Expertise Center for AS in Rotterdam, the Netherlands. We aimed to further delineate the phenotype of AS, to evaluate the association of the phenotype with genotype and other determinants such as epilepsy and to get insight in possible targets for intervention. We confirmed the presence of a more severe phenotype in the 15q11.2-q13 deletion subtype. Novel findings were an association of (early onset of) epilepsy with a negative effect on development, a high occurrence of nonconvulsive status epilepticus, a high rate of crouch gait in the older children with risk of deterioration of mobility, a relatively low occurrence of microcephaly, a higher mean weight for height in all genetic subtypes with a significant higher mean in the nondeletion children, and a high occurrence of hyperphagia across all genetic subtypes. Natural history data are needed to design future trials. With this large clinical cohort with structured prospective and multidisciplinary follow-up, we provide unbiased data on AS to support further intervention studies to optimize outcome and quality of life of children with AS and their family.
PMID: 31729827 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード